KA Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 23.70%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Kineta Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 09/18/2024 10:02 PM ET
Kineta Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/6/2023 | Raymond J Bartoszek | Director | Buy | 250 | $4.50 | $1,125.00 | 17,206 |  |
| 12/4/2023 | Raymond J Bartoszek | Director | Buy | 1,000 | $4.33 | $4,330.00 | 15,956 | |
| 11/28/2023 | Craig W Philips | President | Buy | 3,000 | $3.27 | $9,810.00 | 60,811 | |
| 11/28/2023 | Shawn Iadonato | CEO | Buy | 900 | $3.33 | $2,997.00 | 671,130 | |
| 9/20/2023 | Craig W Philips | President | Buy | 600 | $2.54 | $1,524.00 | 54,911 | |
| 9/20/2023 | Pauline Kenny | General Counsel | Buy | 1,500 | $2.58 | $3,870.00 | 18,448 | |
| 9/20/2023 | Shawn Iadonato | CEO | Buy | 10,000 | $2.50 | $25,000.00 | 670,230 | |
| 9/18/2023 | Keith Baker | CFO | Buy | 5,000 | $2.13 | $10,650.00 | 16,880 | |
| 9/18/2023 | Raymond J Bartoszek | Director | Buy | 2,500 | $2.08 | $5,200.00 | 12,956 | |
| 9/15/2023 | Raymond J Bartoszek | Director | Buy | 500 | $2.18 | $1,090.00 | 10,456 | |
| 9/14/2023 | Thierry Guillaudeux | Insider | Buy | 10,000 | $2.00 | $20,000.00 | 21,696 | |
| 6/16/2023 | Keith Baker | CFO | Buy | 5,000 | $2.92 | $14,600.00 | 11,880 | |
| 3/20/2023 | Craig W Philips | President | Sell | 872 | $3.29 | $2,868.88 | 66,977 | |
| 3/20/2023 | Pauline Kenny | General Counsel | Sell | 544 | $3.29 | $1,789.76 | 17,806 | |
| 3/20/2023 | Shawn Iadonato | CEO | Sell | 1,119 | $3.29 | $3,681.51 | 666,287 | |
| 3/17/2023 | Craig W Philips | President | Sell | 1,231 | $4.94 | $6,081.14 | 67,849 | |
| 3/17/2023 | Pauline Kenny | General Counsel | Sell | 767 | $4.94 | $3,788.98 | 18,350 | |
| 3/17/2023 | Shawn Iadonato | CEO | Sell | 1,580 | $4.94 | $7,805.20 | 667,406 | |
Kineta Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/7/2024 | PFG Investments LLC | 326,988 | $0.17M | 0.0% | N/A | 2.669% |  |
| 2/13/2024 | Armistice Capital LLC | 825,792 | $3M | 0.0% | -11.2% | 7.948% | |
| 11/15/2023 | Armistice Capital LLC | 930,000 | $3.16M | 0.0% | +6.2% | 8.951% | |
| 11/9/2023 | Manchester Capital Management LLC | 10,216 | $35K | 0.0% | N/A | 0.098% | |
| 2/13/2023 | Artal Group S.A. | 31,055 | $0.20M | 0.0% | N/A | 2.004% | |
Data available starting January 2016
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
Read More on Kineta
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
530,700 shs
Average Volume
409,478 shs
Market Capitalization
$7.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.46
